Sobi™ Satellite Symposium

Agenda

Welcome and introduction - Pier Luigi Zinzani (Chair, Italy)

Evolving strategies, evolving challenges in relapsed/refractory diffuse large B-cell lymphoma - Joel Wight (Australia)

Can preclinical data shed a light on treatment sequencing? - Romano Danesi (Italy)

Learnings from clinical trials and real life - Marek Trněný (Czech Republic)

Q&A session and closing remarks - All

Download Slides (2.66 MB)

Publication

EHA •
15 June, 2025 •
•

Economic Burden of Cytopenia in Patients with Myelofibrosis: Analysis of a US National Administrative Claims Database

Aaron T Gerds, Lucia Masarova, Nicole M Engel-Nitz, Michael Marrone, Jefferey McPheeters, Abiola Oladapo, Purvi Suthar, Michael Vredenburg , Yong Zhu, Lindsay AM Rein

Available materials

Poster

Publication

EHA •
15 June, 2025 •
•

Real-world effectiveness of pacritinib in patients with myelofibrosis who have thrombocytopenia and anemia

Raajit Rampal, Samantha Eiffert, Michael Marrone, Lisa Morere, Abiola Oladapo, Anubhav Sharma, Purvi Suthar, Anupama Vasudevan, Michael Vredenburg , John Mascarenhas

Available materials

Poster

Dissecting Treatment Sequencing in Relapsed/Refractory Diffuse Large B-cell Lymphoma From Laboratory to Real Life

Economic Burden of Cytopenia in Patients with Myelofibrosis: Analysis of a US National Administrative Claims Database

Real-world effectiveness of pacritinib in patients with myelofibrosis who have thrombocytopenia and anemia

Real-World Treatment Patterns and Clinical Outcomes in Patients with Myelofibrosis Treated with Pacritinib (PAC) with platelets ≥50 x10^9/L at PAC initiation: Interim results from the MY-PAC Study

Boosting Platelets: Expert Approaches to Adult Immune Thrombocytopenia (ITP)

Hematologic response in patients with myelofibrosis treated with pacritinib in real-word clinical settings

Cytopenia is associated with real-world disease progression and diminished survival in patients with myelofibrosis: Analysis of a US national administrative claims database

Real-world treatment patterns and outcomes in patients with myelofibrosis treated with pacritinib previously treated with ruxolitinib

Putting on your VEXAS goggles: Seeing what’s in plain sight

Dissecting Treatment Sequencing in Relapsed/Refractory Diffuse Large B-cell Lymphoma​ From Laboratory to Real Life

Dissecting Treatment Sequencing in Relapsed/Refractory Diffuse Large B-cell Lymphoma From Laboratory to Real Life